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ALG-2 (apoptosis linked gene 2 product) is a calcium binding protein for which no clear cellular function has been established. In this
study we identiﬁed Scotin as a novel ALG-2 target protein containing 6 PXY and 4 PYP repeats, earlier identiﬁed in the ALG-2 binding
regions of AIP1/ALIX and TSG101, respectively. An in vitro synthesized C-terminal fragment of Scotin bound speciﬁcally to immobi-
lized recombinant ALG-2 and tagged ALG-2 and Scotin were shown by immunoprecipitation to interact in MCF7 and U2OS cell lines.
Furthermore ALG-2 bound to endogenous Scotin in extracts from mouse NIH3T3 cells. Overexpression of ALG-2 led to accumulation
of Scotin in MCF7 and H1299 cells. In vitro and in vivo binding of ALG-2 to Scotin was demonstrated to be strictly calcium dependent
indicating a role of this interaction in calcium signaling pathways.
 2007 Elsevier Inc.
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Open access under CC BY-NC-ND license.ALG-2 was identiﬁed in 1996 in a cell death trap assay
as a proapoptotic protein since expression of ALG-2 anti-
sense RNA inhibited T-cell receptor induced apoptosis in
the 3DO T-cell hybridoma cell line [1]. As ALG-2 is a cal-
cium binding protein of the penta EF-hand protein family
(PEF) [1] with an aﬃnity for calcium in the micromolar
range, similar to calmodulin, it has been suggested that
ALG-2 could be involved in calcium-dependent apoptosis
[2]. However, molecular pathways leading to ALG-2
dependent cell death have not been worked out so far.
Moreover, published work (reviewed in [3] and our unpub-
lished observations) indicate that this protein could also0003-9861  2007 Elsevier Inc.
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Open access under CC BY-NC-ND license.play a role in proliferative processes. An example is its pref-
erential expression in cancer tissues [4].
Several ALG-2 target proteins have been identiﬁed
including AIP1/Alix [5,6], annexins 7, 11 [7] and TSG101
[8], all featuring a proline-rich region. The interaction of
ALG-2 with AIP1/Alix has been studied in some detail
both on a functional and structural level (reviewed in
[9,10]). ALG-2 expression counteracts the anti-apoptotic
properties of a truncated form of AIP1/Alix when
expressed in HeLa cells [5] and it has been reported that
AIP1/ALIX plays a role in endocytosis (reviewed in
[5,10]) and takes part in retrovirus budding [11,12]. ALG-
2 binds AIP1/Alix in a calcium-dependent fashion and
the ALG-2 interacting region of AIP/Alix has been
mapped by two groups independently to a proline-rich
sequence at position 801–812 [13] and 794–826 of human
AIP1/ALIX [9]. Other identiﬁed ALG-2 interacting
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sequences with similarity to the mentioned AIP1/Alix
ALG-2 interacting region. Recently, Sec31A, a novel
ALG-2 binding protein containing as well as proline-rich
sequence was identiﬁed independently by three groups
[14–16]. Binding and colocalization with Sec31A, a coat
component of the ER to Golgi transport vesicle COPII
were found to be Ca2+-dependent [14–16]. It seems there-
fore likely that ALG-2 exerts its calcium dependent func-
tion at least partially at the ER. By searching databases
with the ALG-2 binding sequence of AIP1/Alix in combi-
nation with an ER localization signature we found Scotin.
Scotin was identiﬁed by a diﬀerential display approach
in search for new genes involved in p53-dependent apopto-
sis induced by irradiation of normal and p53 nullizygote
mice [17]. Scotin has the structure of a transmembrane
receptor of type I composed of a signal sequence, a cys-
teine-rich domain, a transmembrane domain and a pro-
line/tyrosine-rich region and is localized to the
endoplasmic reticulum (ER)1 with the proline/tyrosine-rich
domain at the cytosolic face of the ER membrane. Trans-
fection of wt Scotin but not of mutant Scotin lacking the
N-terminal domain promoted apoptosis in a caspase-
dependent manner in tumor cells independently of p53,
indicating that Scotin has an intrinsic pro-apoptotic activ-
ity localized to the N-terminal cysteine-rich domain. Inhi-
bition of endogenous Scotin expression by siRNA
increases resistance to apoptosis induced by UV irradiation
despite strong activation of p53, indicating that Scotin
plays a signiﬁcant role in p53-dependent apoptosis. The
discovery of Scotin brings to light a role of the endoplasmic
reticulum (ER) in p53-dependent apoptosis and prompts
investigation on possible connections with ER-linked pro-
cesses. Here, we provide evidence that ALG-2 binds Scotin
in vitro and in vivo and that overexpression of ALG-2 sta-
bilizes Scotin.Materials and methods
In vitro translation of His-tagged Scotin
Gene-speciﬁc primers for human Scotin encoding amino acids 68–240
were designed with addition of sequences on both upstream and down-
stream primers. Upstream primer: 5 0-ctttaagaaggagatataccatgAGCGAG
GAAAGGTGTGCTGTGCC and downstream primer: 5 0-tgatgatga
gaaccccccccGAGGGCCGCCTTCGGGGCATC (capital letters indicate
gene speciﬁc sequences). The 5 0-ends of the primers overlap with DNA
sequences that contain the coding sequence for the C-terminal His6-tag
and all regulatory elements required for expression in a wheat germ cell-
free expression system. In a second round of PCR the DNA template was
extended with these regulatory DNA sequences supplied in the RTS
Wheat Germ Linear Template Generation Set, His6-tag (Roche Applied
Science). The Scotin cDNA fragment of 172 bp was ampliﬁed from a
placenta cDNA library (Stratagene) with the use of the Advantage—GC 2
PCR kit (Clontech). PCR program: 94 C, 3 min; 35 cycles 94 C, 30 s and1 Abbreviations used: ER, endoplasmic reticulum; GST, glutathione
S-transferase; IPTG, isopropyl-1-thio-b-D-galactopyranoside; IP,
immunoprecipitation.68 C, 2 min followed by a 3 min extra elongation step of 68 C. The
second PCR was performed according to the manufacturer 0s protocol
(Roche Applied Science). From the linear PCR-generated template. Scotin
was expressed in a eukaryotic cell-free protein synthesis system based on a
wheat germ lysate provided by the RTS 100 Wheat Germ CECF kit
according to the manufacturer 0s protocol (Roche Applied Science).
Expression of GST fusion proteins
The cDNA of ALG-2 and the short isoform, ALG-2.1 [2], were cloned
into the pGEX-2TK expression vector downstream of glutathione
S-transferase (GST). Recombinant GST fusion proteins were expressed in
BL21 Escherichia coli cells following transformation with either pGEX-
2TK, pGEX-2TK/ALG-2, pGEX-2TK/ALG-2.1, pGEX-2T-Scotin-4 or
pGEX-2T-Scotin-5. Recombinant GST-Scotin-4 protein was generated by
subcloning the cysteine-rich domain of human Scotin (aa 26 to aa 108)
fused to a FLAG-tag in frame of GST at its C-terminus in the pGEX-6
plasmid. Recombinant GST-Scotin-5 protein was generated accordingly
by subcloning the proline-rich domain of human Scotin (aa 123 to aa 240)
fused to a Flag-tag into the same vector. Expression of the proteins was
induced at OD600 = 0.4 by 1 mM isopropyl-1-thio-b-D-galactopyranoside
(IPTG) for 2 h at 16 or 25 C. Bacteria were harvested by centrifugation at
5000g for 10 min at 4 C and lysed in PBS containing 1 mg/ml lysozyme
followed by 20 min incubation on ice before freezing at 80 C. Thawed
lysates were cleared by centrifugation at 50,000g for 30 min at 4 C and the
GST fusion proteins were puriﬁed on a 1 ml GSTrap FF aﬃnity column
according to the manufacturer 0s protocol (GE Healthcare).
In vitro pull-down assay
Immobilized GST fusion proteins were washed three times in binding
buﬀer (0.5% Nonidet P-40, 150 mM NaCl, 1 mM DTT, 0.1% proteinase
inhibitor mix P8340 (Sigma–Aldrich), 50 mM Tris, pH 7.4) containing
either 1 mMCaCl2 or 1 mMEGTA before use in the pull-down assays. The
Sepharose conjugated GST fusion proteins were incubated with His-tagged
Scotin (residues 68–240) with gentle rotation at 4 C overnight. The same
procedure was followed when ALG-2 covalently bound to NHS-activated
Sepharose beads were used to pull-down His-tagged Scotin. After
incubation the samples were centrifuged at 1000g for 1 min at 4 C.
Supernatants were removed and pellets were washed three times in binding
buﬀer containing either 1 mM CaCl2 or 1 mM EGTA. The GST fusion
proteins were eluted from the glutathione Sepharose beads by addition of
20 mM L-glutathione (GSH) in Tris pH 8 containing 5 mM DTT. The
samples were analyzed on a 12% polyacrylamide gel under reducing and
denaturing conditions and transferred onto a PVDF membrane (Hybond-
P, GE Healthcare). Immunolabeled proteins were detected by HRP
conjugated secondary antibodies followed by the ECL plus chemilumi-
nescence system according to the manufacturer 0s manual (GE Healthcare).
Far Western blot analysis
Bacterial extracts (containing GST-Scotin-4 or GST-Scotin-5) were
run on a 12% polyacrylamide gel and the proteins were transferred onto a
PDVF membrane as described. After blocking for 1 h in AC buﬀer
(containing 10% glycerol, 100 mM NaCl, 20 mM Tris–Hcl, pH 7.4, 0.1%
Tween 20) with 2% low fat milk powder, the membrane was incubated
with 5 lg/ml recombinant ALG-2 in AC buﬀer overnight followed by
extensive washing in AC buﬀer. The membrane was then probed with
ALG-2 antibodies and labeled antibody detected as described above.
Antibodies
Polyclonal antibodies against mouse Scotin were used as described in
[17]. Aﬃnity puriﬁed polyclonal anti-mouse ALG-2 antibodies were used
as previously described [4]. Mouse monoclonal anti-TSG101 antibodies
was from Abcam (Abcam, Cambridge, MA, USA). Mouse monoclonal
anti-His6-Peroxidase conjugated antibodies was from Roche Applied
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made in our laboratory (unpublished). Secondary HRP-conjugated goat
anti-mouse- or goat anti-rabbit-immunoglobulins were from Dako A/S
(Glostrup, Denmark). The monoclonal antibody directed against the
FLAG tag and the monoclonal antibody directed against the HA tag were
purchased from Sigma–Aldrich.Pull-down assay of endogeneous Scotin
NIH3T3 cells were a kind gift from Professor Berthe M. Willumsen.
Cells were grown to conﬂuency and harvested by trypsination. Cell pellets
were suspended in lysis buﬀer containing 10 mM Hepes–NaOH, pH 7.4,
142.5 mM KCl, 0.2% NP-40, 2 mM NaVO4, 20 mM NaF and 0.1% pro-
teinase inhibitor mix P8340 (Sigma–Aldrich), and lysed mechanically by
10 strokes in a Dounce homogenizer. Lysates were spun at 10,000g at 4 C
for 10 min and the protein concentration of the supernatants was adjusted
to 2 mg/ml. Either 10 lM CaCl2 or 1 mM EGTA was added to the lysates
before incubation with control beads or beads conjugated with either
recombinant ALG-2.1 or ALG-2. Recombinant ALG-2.1 and ALG-2
were expressed, puriﬁed and conjugated as previously described [4,18].
Beads were incubated with lysates overnight at 4 C and washed three
times in lysis buﬀer before addition of sample buﬀer (100 mM Tris, pH 6.8,
200 mM DTT, 4% SDS, 0.2% bromophenol blue and 20% glycerol) fol-
lowed by boiling for 2 min. Proteins pulled down from the lysates were
separated by SDS–PAGE (10%), blotted to a PVDF membrane and
immunolabeled with antibodies against Scotin, Tsg101 and AIP1/Alix.Transient transfections
About 1 · 106 H1299, MCF7 or U2OS cells were seeded onto 10-cm
tissue culture plates and transfected 24 h later by Fugene (Boehringer).
Construction of the EGFP-ALG-2 plasmids is described in [16] and the
HA tag was added 5´ of the intact cDNA coding sequence of the ALG-2
variants in the pcDNA3 vector. Typically, 5 lg of expression plasmids for
Scotin and for ALG-2 were transfected per 10 cm plate, unless otherwiseSignal sequence cysteine dom
In vitro 
Transcription/translation [19] 
Product 68 - 240 
Recombinant Scotin 4: 1 - 86 
Recombinant Scotin 5: 114 - 240 
AIP1_795-868_        P-PQAQGPPYPTYPG--YPGYCQ
Scotin_158-240_      PYPQPPSVP-PSYPGPSYQGYHT
TSG101_146-218_      -----ISASYPPYQATGPPNTSY
                     . ... . . *.* .    .   
AIP1_795-868_        PGPQQPSYPFPQPPQQSYYPQQ-
Scotin_158-240_      AGGAAAPYPASQPPYNPAYMDAP
TSG101_146-218_      PATTSSQYPS-QPPVTTVGPSRD
High similarity between 
Scotin and AIP1/ALIX 
a
b
Fig. 1. (a) Structure of Scotin and (b) sequence alignment by the ClustalW p
NP_037506, TSG101, Accession No. NP_006283 and Scotin (Accession No. NP
or in two sequences.stated. The DNA amount was normalized to 10 lg with pcDNA3 vector
or as otherwise stated.Immunoprecipitation
For immunoprecipitation (IP), H1299 MCF7, or UO2 S cells were
transfected and treated as indicated. Upon treatment, cells were ﬁxed with
1% formaldehyde for 10 min at 37 C, and then blocked for 5 min in
125 mM glycine at room temperature. Proteins were extracted using a lysis
buﬀer containing 50 mM Tris, pH 7.5, 1% Triton X-100, 0.27 M sucrose,
NaCl 100 mM, complete protease inhibitor cocktail (Roche Applied Sci-
ence) and passed several times through a narrow gauge needle. The
immunoprecipitating antibody was covalently coupled to protein
G-Sepharose using the dimethyl pimelimidate method. For each IP 2 lg of
antibody was coupled to 20 ll of packed volume protein G-Sepharose and
incubated with 1 mg of cell extract for 1 h at 4 C. IPs were washed four
times in 1 ml of IP buﬀer. The immunoprecipitated proteins were eluted
end-over-end for 30 min at ambient temperature in 50 ll of Laemmli
sample buﬀer and boiled with 5% (v/v) b-mercaptoethanol, prior to SDS–
PAGE (NuPAGE pre-cast 12% gels using MES running buﬀer from
Invitrogen). For Western-blots proteins were extracted and analyzed as
previously described [19].Results
Scotin contains putative ALG-2 binding motifs
Elucidation of the binding of ALG-2 to TSG101, AIP1/
Alix, Annexin 7 and 11 (reviewed in [3]) encouraged
database searches for protein sequences containing similar
proline/tyrosine-rich regions with the goal to ﬁnd novel
ALG-2 binding partners. One of the candidate proteins
found by this in silico approach was Scotin (Fig. 1a).Transmembrane domain








High similarity between 
Scotin and TSG101 
rogram of the proline/tyrosine-rich regions of AIP1/Alix (Accession No.
_057563). Highlighted residues were either identical in the three sequences
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with known ALG-2 interaction partners revealed that the
proline-rich region of Scotin does contain six PXY repeats
(residues 166–168, 171–173, 196–198, 206–208, 225–227,
229–231) as described for the ALG-2 binding region in
AIP1/ALIX [9] and 4 PYP repeats (residues 157–159,
189–191, 197–199, 219–221) as well as 1 YPP sequence (res-
idues 194–196), as described for the ALG-2 binding region
in TSG101 [8] (Fig. 1b).
Comparisons of the proline-rich region of Scotin (res-
idues 157–240) with AIP1/Alix and TSG101 revealed
that the N-terminal part of this region (residues 157–
177) has highest similarity with the ALG-2 interacting
sequence of AIP1/ALIX (residues 794–812), which has
been shown to be suﬃcient for the interaction with
ALG-2 [13]. The C-terminal adjacent region in ScotinCaCl2
 kDa
+ +
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b c
Fig. 2. In vitro interaction of ALG-2 with Scotin. (a) In vitro pull-down assay
(lanes 3 and 4); GST (lanes 5 and 6) and ALG-2 (lane 7) bound to glutathione
tagged Scotin fragment in the presence of either 1 mM CaCl2 (lanes 1, 3, 5, 7 an
were eluted from beads using GSH and all others by boiling the beads in loading
(b) Far Western blot analysis. Proteins from bacteria extracts (either total fract
by SDS–PAGE, blotted on a PVDF membrane and incubated with recombin
extract; lane 2, Scotin-4, soluble fraction; lane 3, Scotin-5, total extract; lane 4
lanes 1 and 3 in (b). Western blot analysis of GST-ﬂag-Scotin-4, lane 1, and G
Flag epitope.(residues 178–207) has higher similarity to TSG101 (res-
idues 163–192) [13].ALG-2 directly binds to Scotin in vitro
In order to examine binding between Scotin and ALG-2,
we synthesized the predicted ALG-2 interacting protein
fragment of Scotin in vitro. The fragment encoding amino
acid residues 68–240 was ampliﬁed from a placenta cDNA
library (Fig. 1a). At the 3 0-end of the coding region a
sequence encoding a His-tag was added and the PCR prod-
uct was directly used as template in an in vitro transcrip-
tion/translation system. The produced His-tagged Scotin
fragment was then used in pull-down assays with either
GST, GST-ALG-2, GST-ALG-2.1 or recombinant+ + +







of Scotin fragment by ALG-2. GST-ALG-2.1 (lanes 1 and 2); GST-ALG-2
-Sepharose beads or beads alone (lane 8) were incubated with C-term His-
d 8) or 1 mM EGTA (lanes 2, 4 and 6). Samples containing GST-proteins
buﬀer. Four percentage of the Scotin fragment input was loaded in lane 9.
ions or soluble proteins) containing human Scotin-4 and -5 were separated
ant ALG-2 followed by probing with anti-ALG-2. Lane 1, Scotin-4, total
, Scotin-5, soluble fraction. (c) Equal loading control of total extracts as
ST-ﬂag-Scotin-5, lane 2, visualized using an antibody directed against the
I. Dræby et al. / Archives of Biochemistry and Biophysics 467 (2007) 87–94 91ALG-2 directly conjugated to NHS-activated beads or
non-conjugated control beads.
ALG-2 was able to pull-down the Scotin fragment in a
calcium dependent manner (Fig. 2a, top panel, lanes 3
and 4), whereas the two amino acids shorter ALG-2.1 iso-
form was unable to bind the Scotin fragment (Fig. 2a, top
panel, lanes 1 and 2). Scotin could be pulled down under
calcium conditions when ALG-2 was directly conjugated
to beads (Fig. 2a, top panel, lane 7), but not with control
beads (Fig. 2a, top panel, lane 8). Equal amounts of bait
protein used for pull-down of Scotin were conﬁrmed using
antibodies against ALG-2 (Fig. 2a, middle panel) and GST
(Fig. 2a, bottom panel). The strong signal in Fig. 2a, mid-
dle panel, lane 7 is probably due to noncovalent recombi-
nant ALG-2 dimerization formed during conjugation.
The presence of the bands of nonfused ALG-2 (Fig. 2a,
middle panel lanes 1–4) and GST (Fig. 2a, bottom panel
lanes 1–6) indicates that the GST-ALG-2 protein is unsta-
ble following sample buﬀer treatment.
To conﬁrm direct binding of ALG-2 to Scotin variants
we carried out Far Western blots using immobilized recom-
binant GST-Scotin (Fig. 2b and c). GST-Scotin-4 and
GST-Scotin-5 fragments (Scotin-4 containing the N-termi-
nal part and Scotin-5, containing the C-terminal fragment
of Scotin with the proline-rich sequence, see Fig. 1a) fused
to GST were expressed in bacteria and total extracts as well
as soluble fractions were analyzed on a Far Western blot
using recombinant ALG-2 as a probe. A strong single sig-Fig. 3. Co-immunoprecipitation of Scotin with ALG-2 after co-transfection. (a
in MCF-7 cells. Human Scotin-Flag and HA-tagged ALG-2 or GFP fused
immunoprecipitation of Flag-tagged Scotin with GFP-ALG-2 fused proteins in
cells is calcium-dependent in vivo. (b and c) Human Scotin-ﬂag was co-transfec
as follows: 1: empty vector and GFP, 2: Scotin-ﬂag and GFP, 3: Scotin-ﬂag an
and variant GFP-ALG-2.1. Forty-eight hours after transfection, proteins
immunoprecipitated (IP) as described in Material and methods using the HA
ionomycin (2 lM), proteins were extracted in IP lysis buﬀer and treated as des
antibody as indicated. Scotin was revealed using Flag monoclonal antibodies
control. Actin was used as a loading control.nal was detected in total lysates from GST-Scotin-5
expressing bacteria (Fig. 2b, lane 3), but no signal was seen
in the soluble fraction (Fig. 2b, lane 4) and in total lysates
as well as in the soluble fraction from of GST-Scotin-4
expressing bacteria (Fig. 2a and b, lanes 1 and 2) even
though a similar amount of GST-Scotin-4 and GST-Sco-
tin-5 was loaded on the gel (Fig. 2c) as demonstrated by
probing for FLAG. These results conﬁrm that the C-termi-
nal part of Scotin binds to ALG-2.Tagged ALG-2 and Scotin interact in vivo as shown by
immunoprecipitation
To determine whether Scotin interacts with ALG-2 in a
cellular environment, MCF7 cells were cotransfected with
Scotin-FLAG tagged expression vectors in the presence
or absence of HA-tagged ALG-2. Cells were harvested
48 h after transfection and protein extracts were incubated
with HA monoclonal antibody for co-immunoprecipitation
experiments (Fig. 3a). Scotin (theoretical size of 28 kDa)
gives three bands (28, 25 and 17 kDa) after transfection
in MCF-7 cells. All forms of Scotin co-immunoprecipitated
with HA-ALG-2.
To determine whether the interaction between ALG-2
and Scotin was speciﬁc, FLAG-tagged Scotin-was cotrans-
fected in MCF7 cell lines with diﬀerent ALG-2 variants
fused to EGFP or EGFP alone. Proteins were extracted
48 h after transfection and incubated with GFP antibody) Co-immunoprecipitation of Flag-tagged Scotin with HA-tagged ALG-2
ALG-2 variants were transfected as indicated in MCF-7 cells. (b) Co-
MCF-7 cells. (c) Co-immunoprecipitation of Scotin with ALG-2 in U2OS
ted for 48 h in cells with GFP or GFP- ALG-2 variants expression vectors
d GFP-ALG-2, 4: Scotin-ﬂag and mutant GFP-ALG-2EF, 5: Scotin ﬂag
extracted (1 mg) in IP buﬀer supplemented with 1 mM CaCl2 were
or the GFP monoclonal antibodies. (c) Immediately after treatment with
cribed using anti-GFP antibody. ALG-2 was visualized using HA or GFP
. One percentage of the amount of protein used in the IP was used as a
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variant co-immunoprecipitated with Scotin. Interestingly,
the ALG-2.1 variant and the ALG-2-EF mutant that does
not bind calcium, do not co-immunoprecipitate with any
form of Scotin although the ALG-2.1 and mutant ALG-
2-EF are expressed at the same level as ALG-2.
To determine whether the interaction between ALG-2
and Scotin was calcium-dependent in vivo, Scotin-FLAG
was cotransfected in U2OS cell lines with the three ALG-
2 variants fused to EGFP or EGFP alone. Forty-eight
hours after transfection, cells were treated or not treated
with ionomycin (2 lM) to increase the intracellular calcium
concentration. Proteins were extracted and incubated with
GFP antibody beads for immunoprecipitation (Fig. 3c). In
the absence of ionomycin, consistent with the results
obtained in vitro only EGFP-ALG-2 co-immunoprecipi-
tated with Scotin but not the variant ALG-2.1 and the
mutant ALG-2-EF. Only the 28/25 kDa Scotin forms inter-
act with ALG-2 upon ionomycin treatment. This indicates
that the interaction between Scotin and ALG-2 is calcium-
dependent in vivo and that in U2OS cells the 17 kDa Scotin
species does not interact with ALG-2.
Endogeneous Scotin binds to recombinant ALG-2
The ability of ALG-2 to bind endogenous mouse Scotin
was tested in protein extracts from NIH3T3 cells. Scotin
was expressed at a detectable level in NIH3T3 cells without
induction of p53 (Fig. 4, lane 7). Scotin could be pulled
down by ALG-2-beads from the lysates of NIH3T3 cells,
however, with lower eﬃciency as compared to TSG101
(Fig. 4, lanes 3 and 7). We also conﬁrmed that the Scotin
interaction with ALG-2 was speciﬁc for the long form of
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Fig. 4. In vivo pull-down assay of mouse Scotin by recombinant ALG-2.
Sepharose beads with ALG-2.1 (lanes 1 and 2) or ALG-2 (lanes 3 and 4)
and control beads (lanes 5 and 6) were incubated with NIH3T3 cell lysates
either in the presence (1, 3, 5) or in the absence (2, 4, 6) of Ca2+ (10 lM).
Pulled down proteins or total lysate (T) (lane 7), representing 1/50 of the
input were resolved by SDS–PAGE and blotted to a membrane, which
was immunolabeled with the indicated antibodies.2.1-beads did not pull-down mouse Scotin from NIH3T3
lysates (Fig. 4, lanes 1 and 2). In addition, the binding of
ALG-2 to Scotin from cell lysates required the presence
of Ca2+ (Fig. 4, lane 3 and 4). As a positive control we
show that antibodies directed against the previously
described ALG-2 binding partners, AIP1/Alix [6] and
TSG101 [8] reacted with the corresponding antigens in
ALG-2 pull-downs from NIH3T3 cell lysates. It should
be noted that the presence of a strong ALG-2 signal in
the ALG-2.1 and ALG-2 pull-down lanes in Fig. 4 is due
to recombinant ALG-2 eluted from the ALG-2 beads fol-
lowing boiling of the samples (as is also seen in Fig. 2)
which served as a loading control. The NIH3T3 cells
express small amounts of ALG-2. However, this is only vis-
ible by longer exposures of the ﬁlm (data not shown).
ALG-2 stabilizes Scotin
In initial experiments to study the interplay between Sco-
tin andALG-2,H1299 andMCF7 cellswere transfectedwith
Scotin-FLAG tagged expression vectors in the presence or
absence of HA-tagged ALG-2. Proteins from H1299 and
MCF7were extracted 24 and 48 h after transfection and ana-
lyzed by Western blot (Fig. 5). After 24 h of transfection in
H1299, the humanScotin-FLAGexpression vector gives rise
to two bands speciﬁcally revealed by the FLAGantibody (28
and 25 kDa), while three Scotin bands are revealed inMCF7
protein extracts (28, 25 and 17 kDa) as previously observed
(see Fig. 3). After 48 h of transfection, the FLAG antibody
revealed three bands in H1299 (28, 25 and 17 kDa) with
the 25 kDa band being the most abundant. However, 48 h
after transfection in MCF7 cells, Scotin is mostly a 17 kDa
protein with the 28 and 25 kDa Scotin forms are barely
detectable. We observed the same patterns of bands after
transfection of untagged human Scotin and mouse Scotin
protein in MCF7, H1299, and U2OS cells (data not shown).
The addition of MG132, an inhibitor of proteasomal degra-
dation, calpain, cathepsin and cysteine proteases, onto Sco-
tin transfected cells stabilized the 28/25 kDa Scotin form
indicating that Scotin is cleaved in vivo by one or more of
these proteases (data not shown). As the FLAG-tag is
located at the C-terminus end of Scotin, we suggest that
the 17 kDa bands is the result of the cleavage in the N-termi-
nal domain of the 28/25 kDa Scotin protein giving rise to a
truncated Scotin protein deleted of the cysteine-rich pro-
apoptotic domain.
To determine whether stabilization of the Scotin 28/
25 kDa forms was dependent on the amount of ALG-2,
we cotransfected in parallel H1299 and MCF7 cells with
FLAG-tagged Scotin and an increasing amount of ALG-
2 or ALG-2.1 expression vectors. Cells were harvested in
parallel 24 and 48 h after transfection. Twenty-four hours
after transfection of H1299 cells, the 25 kDa Scotin form
is accumulated in ALG-2 and in ALG-2.1 transfected cells
(Fig. 5a). Twenty-four hours after transfection in MCF-7
cells, the 28, 25 and 17 kDa Scotin bands showed a higher
abundance in ALG-2 than in ALG-2.1 transfected cells
Fig. 5. ALG-2 stabilizes Scotin (Western blot). MCF-7 and H1299 cells were co-transfected in parallel with Scotin-Flag (2 lg) and pcDNA3 empty
expression vector (3 lg) or an increasing amount of HA-ALG-2 or of HA-ALG-2.1 expression vectors (0.5, 1.5 and 3 lg). For all transfection, the ﬁnal
concentration of DNA was adjusted to 5 lg using pcDNA3 empty expression vector. Proteins were extracted in RIPA buﬀer 24 h (a) and 48 h (b) after
transfection. Twenty micrograms protein extract was analyzed by Western blot. Scotin was revealed using Flag antibody. ALG-2 and ALG.1 were
revealed by HA antibody. Actin was used a loading control.
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Forty-eight hours after transfection in H1299 cells, the
25 kDa Scotin isoform but not the 28 and 17 kDa forms
are accumulated in an ALG-2 dose-dependent manner
(Fig. 5b). The variant ALG-2.1 promotes accumulation of
the 28/25 kDa Scotin forms to a lesser degree. Forty-eight
hours after transfection in MCF7 cells, the major Scotin
form is the 17 kDa protein. However, co-transfection of
ALG-2 with Scotin promotes strong accumulation of the
28, 25 and 17 kDa Scotin forms in an ALG-2 dose-depen-
dent manner. The ALG-2.1 variant seems again to be less
active than ALG-2 to promote accumulation of the 28 and
25 kDa Scotin species although ALG-2 and ALG-2.1 are
expressed at similar levels. This indicates that ALG-2 and
ALG-2.1 can stabilize and inhibit cleavage of Scotin. How-
ever, depending on the cell lines, ALG-2.1 may be less eﬃ-
cient compared to ALG-2 to stabilize Scotin.
Discussion
By utilising the so far available information on ALG-
2 target recognition sites, we were able to identify Scotinas a novel ALG-2 interacting protein. Comparison of the
Scotin sequence with the mapped ALG-2 binding
sequence in AIP1/Alix and putative ALG-2 recognition
sequences in other ALG-2 targets, Annexin 7, 11, and
TSG101, led us to predict that in human Scotin, it is
the sequence region between position 158 and 222, which
is responsible for ALG-2 binding. However, only map-
ping experiments will show whether this is correct. A fur-
ther indication that binding takes place within this
sequence is given by the ﬁnding that the interaction
between ALG-2 and Scotin shows several features in
common with ALG-2 binding to other target proteins.
The interaction is calcium dependent and it does not
take place with the ALG-2 splice variant ALG-2.1, as
is also the case for the AIP1/ALIX and TSG101 interac-
tion with ALG-2 [8,9].
By sequence alignment it was found that ALG-2
belongs to the group of penta EF-hand calcium binding
proteins [1]. Later, we showed that the aﬃnity for cal-
cium is in the lM range indicating that ALG-2 could
sense physiological calcium transients similar to calmod-
ulin [2]. It has been known since many years that cal-
cium is an important signaling molecule in apoptosis
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as calmodulin, S-100, calcineurin and calpain have been
shown to modulate apoptotic processes [20,21]. However,
only few pathways with well-deﬁned molecular mecha-
nisms have been established. One of these is the activa-
tion of the pro-apoptotic protein Bcl-2 family protein
Bad by calcineurin, which dephosphorylates the former
protein, enabling it to relocate to the mitochondria and
exert its pro-apoptotic function [22].
The endoplasmic reticulum is the main intracellular cal-
cium store and mechanisms that regulate intake and release
of calcium from the ER are highly regulated. Disturbance
of such mechanisms, e.g. failure of IP3 receptor function
(reviewed in [23]) may lead to cell death. Several ER mem-
brane linked proteins have been shown to be potential
players in calcium-dependent apoptosis (reviewed in [23]).
Rao et al. [24] have shown that ALG-2 mediates the ER
stress induced apoptotic pathway. Thapsigargin but not
Brefeldin A induced cell death was to some degree reduced
when the ALG-2 levels were reduced by transfection of
cells with ALG-2 siRNA, indicating that ALG-2 has a spe-
ciﬁc function in ER-stress induced cell death. Here we
report that the ER localized Scotin, which is expressed as
a 28/25 and 17 kDa protein in MCF7, H1299 and U2OS
cell lines, is stabilized after transfection of ALG-2 leading
to accumulation of the 28/25 kDa forms. This eﬀect is
ALG-2 speciﬁc as the variant ALG-2.1 as well as the
mutant ALG-2-EF are deﬁcient or less eﬀective in accumu-
lating the 28/25 kDa form of Scotin. As treatment of Sco-
tin transfected cells with MG132, an inhibitor of cellular
proteolytic activity, also stabilizes in vivo the 28/25 kDa
Scotin forms, ALG-2 might protect Scotin from proteolytic
degradation. Since the N-terminus of Scotin, needed for its
apoptotic function [17], is partially lost if ALG-2 is only
present at low levels, ALG-2 might modulate the apoptotic
function of Scotin. Further studies will be required to
determine whether the direct interaction between ALG-2
and Scotin is involved in the observed stabilization and
what are the biological consequences of Scotin
stabilization.
Based on our ﬁndings, we speculate that ALG-2 and
Scotin are functionally linked in the regulation of signal
transduction leading to calcium and ER-dependent apop-
tosis. One possible regulatory mechanism could be that
ALG-2 is brought to the ER when calcium is transiently
increased in the cell followed by interaction with and mod-
ulation of Scotin or other ER localized proteins. How the
interaction of ALG-2 with Scotin would aﬀect the function
of the latter protein and/or calcium handling processes in
the ER and what could be the signiﬁcance of this protein
interaction in apoptosis remain open questions. One possi-
bility is the modulation of the regulation of the ER to
Golgi protein transport since ALG-2 binds Sec31A, which
is a component of the COPII particle [9]. This paper
reports on the interaction between Scotin and ALG-2
and the stabilization of Scotin upon ALG-2 expression. It
is a ﬁrst step towards the understanding of a novel andcomplex endoplasmic reticulum-dependent apoptotic
pathway.
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